Royalty Strategy AnaptysBio’s core focus on managing Jemperli and imsidolimab royalties positions it as a potential client for royalty analytics, licensing management software, and advisory services to optimize cash flows, milestones, and compliant reporting as partnerships mature.

Growth and Alliances With a Q1 financial update and a new CFO, the company signals expanded financial governance and potential for scaling collaborations, creating opportunities to sell alliance-management platforms, FP&A tools, and cloud-based ERP integrations to support additional partnerships and revenue tracking.

Partnership Expansion Existing collaborations with GSK and Vanda indicate readiness to engage in more pharma/biotech partnerships, suggesting needs for due diligence support, contract analytics, and licensing negotiations services to accelerate deal closure and value realization.

Investor Relations Public market activity and analyst coverage imply demand for investor relations services, including performance dashboards for royalty streams, press release support, and investor communications platforms that clearly articulate collaboration returns to shareholders.

Digital Marketing The tech stack shows active website and analytics usage (Drupal, Google Search Console, Adobe Tag Manager, Piwik PRO Core), presenting an opportunity to offer digital presence optimization, data privacy/security hardening, and regulatory communications tooling to improve visibility and compliance.